The Bear Cave • 629 implied HN points • 05 Jan 25
- Hims & Hers Health could be in trouble if the FDA removes its shortage label on semaglutide, which would stop them from selling compounded versions of the drug.
- Recent reports revealed Carvana's questionable dealings related to $800 million in loan sales and a possible SEC investigation, leading to a significant drop in their stock.
- There have been several high-profile executive resignations recently, indicating potential instability in companies like Integral Ad Science and Aurora Innovation.